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Acrylamide (AA) is formed in heat treated carbohydrate rich
foods in the so-called Maillard reaction. AA is readily absorbed in
the body and converted to glycidamide (GA) by epoxidation by the
CYP2E1 (cytochrome P450 2E) enzyme. Both AA and GA may be
detoxiﬁed through direct conjunction to glutathione by glutathi-
one-S-transferases and GA by hydrolysis to glyceramide. Recently,
we reported that biomarkers of AA exposure reﬂect intake of
major food sources of AA; there were large interindividual
variations in the blood ratio of GA-Hb/AA-Hb (GA- and AA-
hemoglobin adducts). In this study we investigated whether the
ratio of GA-Hb/AA-Hb in subjects could be related to polymorphic
differences in genes coding for metabolizing enzymes CYP2E1,
EPHX1 (microsomal epoxide hydrolase), GSTM1, GSTT1, and
GSTP1, all being expected to be involved in the activation and
detoxiﬁcation of AA-associated adducts. We found signiﬁcant
associations between GSTM1 and GSTT1 genotypes and the ratio
of GA-Hb/AA-Hb (p 5 0.039 and p 5 0.006, respectively). The
ratio of GA-Hb/AA-Hb in individuals with the combined GSTM1-
and GSTT1-null variants was signiﬁcantly (p 5 0.029) higher than
those with the wild-type genotypes. Although the number of
subjects was small, there were also signiﬁcant associations with
other combinations; CYP2E1 (Val179Val) plus GSTM1-null (p 5
0.022); CYP2E1 (Val/Val), GSTM1-null plus GSTT1-null (p 5
0.047); and CYP2E1 (Val/Val), GSTT1 null, EPHX1 (Tyr113Tyr)
plus EPHX1 (His139Arg) (p 5 0.018). Individuals with these
combined genotypes had signiﬁcantly higher blood ratio of GA-
Hb/AA-Hb than other combinations. The observed associations
correspond with what would be expected from the relative roles of
these enzymes in activation and detoxiﬁcation of AA, except for
individuals with the EPHX1 (His139Arg) variant. The internal
dose of genotoxic metabolite and also the concentration of AA in
blood seem to be affected by these polymorphic genes. The
genotypes and their combination may constitute useful bio-
markers for the assessment of individual susceptibility to AA
intake, and could add to the precision of epidemiological studies
of dietary cancer.
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The Maillard reaction is responsible for the formation of
browning products contributing to color, odor and taste of
processed food (Ho, 2006). Maillard browning reaction
products from mainly glucose and asparagine are responsible
for the formation of acrylamide (AA) in foods (Mottram et al.,
2002; Stadler et al., 2002). The presence of AA in foods caused
considerable concern because AA is classiﬁed by IARC (1994)
as probably carcinogenic to humans (2A). AA is readily
absorbed and metabolized in the body. A major detoxiﬁcation
pathway is glutathione conjugation, resulting in urinary
excretion of N-acetyl-S-(3-amino-3-oxopropyl) cysteine, a mer-
capturic acid derivative (MA-AA) (Sumner et al., 1992, 1997).
An alternative metabolic pathway is the CYP2E1 (cytochrome
P450 2E1) dependent oxidation of AA, from which the
genotoxic epoxide glycidamide (GA) is formed (Ghanayem
et al., 2005; Sumner et al., 1999). GA reacts readily with DNA
and other macromolecules forming adducts (Dearﬁeld et al.,
1995; Segerback et al., 1995) and this is probably the main
pathway responsible for the carcinogenic effect of AA. GA
may, however, also be further metabolized by epoxide
hydrolase (EPHX1) to glyceramide, which is excreted in
urine (Kirman et al., 2003) or conjugated to glutathione, and
these reactions represent deactivation pathways and therefore
compete with the formation of GA adducts. Following a
stepwise conversion, the GA-glutathione conjugates are excreted
as the urinary MA derivatives N-acetyl-S-(3-amino-2-hydroxy-
3-oxopropyl)cysteine (MA-GA3) and N-acetyl-S-(carbamoyl-
2-hydroxyethyl)cysteine (MA-GA2) (Sumner et al., 1992).
There are nonenzymatic pathways for the transformation of AA
and GA but these are considered to be less signiﬁcant in vivo.
AA may also interact covalently in vivo with proteins forming
different types of macromolecular adducts (Doerge et al., 2005;
Tornqvist et al., 2002). Hemoglobin (Hb) adducts of AA and
GA represent an integral of AA and GA concentrations present
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use, please contact journals.permissions@oxfordjournals.org.in the circulation over the lifetime of the erythrocytes (about
4 months) and reﬂect therefore the average exposure to AA
over the last months (Hagmar et al., 2005).
Genes coding for enzymes involved in the biotransformation
of carcinogens can be used as markers of individual suscepti-
bility to cancer because different activity of these enzymes may
increase or decrease the conversion of a xenobiotic into its
reactive metabolite. A large number of chemical carcinogens are
biotransformed to more toxic metabolites by phase I activation
enzymes, such as CYPs or to nontoxic compounds by phase II
detoxiﬁcation enzymes, such as glutathione-S-transferase
(GSTs). Many enzymes involved in either activation or detoxi-
ﬁcation of chemical carcinogen metabolism are polymorphically
expressed, with the alleles presenting different enzymatic
activities (Autrup, 2000). CYP2E1 is an enzyme responsible
for the metabolic activation of many carcinogens, including AA;
this inducible and major CYP isoform is mainly expressed in the
liver, but is also found at signiﬁcant levels in other human
tissues. The important role of CYP2E1 in epoxidation of AA to
GA and formation of GA-DNA adducts has been demonstrated
100 by using CYP2E1-null mice, and when such mice were
exposed to AA, higher levels of AA-adducts were observed
compared with wild-type mice (Ghanayem et al.,2 0 0 5 ;S u m n e r
et al.,1 9 9 9 ) .
The microsomal EPHX1 is involved in the metabolism of
highly reactive epoxide intermediates and presumably also GA,
to the less reactive and water-soluble glyceramide. It has been
shown that the activity of the enzyme EPHX1 is affected
by two polymorphisms; a substitution of 113Tyr to 113His
in exon 3 corresponds to a 40% decrease in the enzyme
activity, whereas a substitution of 139His to 139Arg in exon
4 corresponds to a 25% increase in the enzyme activity
(Benhamou et al., 1998; Hassett et al., 1994). It has been
shown that the resulting activity of EPHX1 depends on its
expression level, measured with benzo[a]pyrene-4,5-oxide and
cis-stilbene oxide as substrates (Hosagrahara et al., 2004;
Omiecinski et al., 2000).
GSTs constitute a superfamily of at least 13 isoenzymes
belonging to ﬁve different families, in humans designated
alpha, gamma, mu, pi, and theta (Mannervik et al., 1992;
Meyer et al., 1991). GSTs are known to play important roles in
the defense system against damaging effects of oxidative stress
as well as reactive electrophiles. In humans, there are three
GST genes, GSTM1, GSTT1, and GSTP1, with known
functional polymorphisms (Ali-Osman et al., 1997; Board,
1981; Pemble et al., 1994; Peter et al., 1989). Because the
speciﬁcity and also expression level of the GST isoenzymes
affect the biotransformation of most toxic electrophiles, the
existence of different variants of the enzymes may inﬂuence
the detoxiﬁcation efﬁciency. The homozygous deletion poly-
morphisms of the GSTM1 and GSTT1 genes, as well as the
GSTP1 105Val allele polymorphism, are known to alter
enzyme activities (Cotton et al., 2000; Hayes and Strange,
1995). It has been suggested that individuals who are
environmentally exposed to carcinogens and also carry genetic
variants of genes for phase I or phase II enzymes, have a higher
risk of developing cancer (Autrup, 2000). This may also apply
to AA, a possibility which is explored in the present work.
Recently, we reported on methods to determine the Hb
adducts of AA and GA in blood (Bjellaas et al., 2007). These
biomarkers of exposure to AA were quantiﬁed in blood
samples from volunteers and correlated to dietary intake as
recorded in food frequency questionnaires (Bjellaas et al.,
2007). The relationship between the estimated dietary intake of
AA and Hb adducts in this cohort has been described in detail
elsewhere (Bjellaas et al., 2007). We found signiﬁcant
correlations between the biomarkers and major known food
sources of AA. The molar ratio between GA-derived and AA-
derived Hb adducts varied considerably (ninefold) between the
individuals (Bjellaas et al., 2007), and the varying ratio of GA-
Hb/AA-Hb among individuals could not be explained by the
AA intake alone. This could reﬂect individual differences in
metabolizing capacity. Recently, it was reported that there are
large variations in AA-Hb and GA-Hb adducts between
individuals, and between subpopulations in Europe (Vesper
et al., 2008). We have therefore characterized our study
subjects with respect to polymorphisms in CYP2E1, EPHX1,
GSTM1, GSTT1, and GSTP1, and explored associations
between given combinations of these polymorphisms and the
amount of AA and GA adducts as well as their ratio.
METHODS
Subjects. Forty-seven nonsmoking employees at the Norwegian Institute
of Public Health accepted an invitation to participate in the study. In addition,
six smokers were recruited through personal invitation. There were no
exclusion criteria, but samples from four participants (two male and two
female) were left out of the study because all of the blood had been used for
adduct measurement. In total, the study population consisted of 49 participants,
18 males, and 31 females. A detailed description of the subjects was also given
in our previous report (Bjellaas et al., 2007). Two males and four females were
smokers (12% of the study population); the median number of cigarettes per
day was 14 (range 7–21). All individuals examined were Caucasians. The
Regional Ethics Committee and the Data Inspectorate approved the study, and
all participants gave their written informed consent.
Determination of hemoglobin adducts of AA and GA. Hb adducts of AA
and GA were determined as phenylthiohydantoin derivatives and quantiﬁed
using liquid chromatography with an ion trap tandem mass spectrometric
detection in negative electrospray ionization mode. The preparation of blood
samples and determination of Hb adducts have been described in detail
previously (Bjellaas et al., 2007), and the same methods for the determination
of Hb adducts were used recently (Olesen et al., 2008).
Genotyping. Genomic DNA was extracted from frozen whole blood from
the 49 subjects using BloodPrep Chemistry on the ABI PRISM 6100 Nucleic
Acid PrepStation (Applied Biosystems, Foster City, CA) according to the
manufacturer’s instructions, and the quantity and quality of isolated DNA was
determined using a NanoDrop Spectrophotometer (Thermo Scientiﬁc, Waltham,
MA). The presence or absence of GSTM1 and GSTT1 genes were determined
with PCR, using GSTM2 as a positive control. The primers used for GSTT1 were
5#-CAT CTC CTT AGC TG ACCT CGT AG-3# and 5#-GGC ATC AGC TTC
TGC TTT ATG-3#, generating a 412-base pair (bp) fragment (Abdel-Rahman
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G-3# and 5#-CTG GAT TGT AGC AGA TCA TGC-3#, generating a 276-bp
fragment (Ryberg et al., 1994). The primers for GSTM2 were 5#-C T GC C C
TAC TTG ATT GAT G-3# and 5#-GAC TCA CTC TGA GCA TAG CAC-3#,
generating a 165-bp fragment (Ryberg et al., 1994). The absence of a 412- or
a 276-bp electrophoretic band in the PCR product indicates the presence of a
GSTM1-null or a GSTT1-null genotype, respectively. The presence of a 165-bp
band of GSTM2 indicates successful PCR assay.
The TaqMan single nucleotide polymorphism (SNP) Genotyping Assay was
used for CYP2E1, EPHX1, and GSTP1 according to the manufacturer’s
protocol (Applied Biosystems). Brieﬂy, each reaction mixture (13.75 ll) of
polymerase chain reaction contained 50 ng of DNA, 12.50 llo f2 3 TaqMan
Universal PCR Master Mix, No AmpErase UNG, and 1.25 llo f2 0 3 TaqMan
SNP Genotyping Assay Mix (primers and probes speciﬁc for each poly-
morphism) (Applied Biosystems). Ampliﬁcation was done under the following
conditions: 50C for 2 min, 95C for 10 min followed by 50 cycles of 92C for
15 s and 60C for 1.5 min. Data were analyzed using Allelic Discrimination
Program (Applied Biosystems). For each polymorphism, all 49 DNA samples
were genotyped at least twice to conﬁrm the results. The primer and probe used
were: CYP2E1 Val179Ile polymorphism (rs6413419), CYP2E1 Phe421Phe
polymorphism (rs2515641), EPHX1 Tyr113His polymorphism (rs1051740),
EPHX1 His139Arg polymorphism (rs2234922), and GSTP1 Ile105Val poly-
morphism (rs1695), and all reagents and the 7500Fast Real-Time PCR System
are from Applied Biosystems (Applied Biosystems).
Statistical analysis. The difference in mean molar ratios between the GA
and AA Hb adducts in blood was analyzed with the nonparametric, Mann–
Whitney U test. The Chi-squared goodness-of-ﬁt test was used to examine the
distributions of subjects with the polymorphic genotypes between genders, and
this test was also used to compare the allele proportions and to determine
whether the CYP2E1, EPHX1, and GSTP1 allelic frequencies conformed with
the Hardy-Weinberg equilibrium. Deviations from Hardy-Weinberg equilib-
rium for GSTM1 and GSTT1 individuals were not tested, because
heterozygous individuals could not be distinguished from wild-type by the
PCR method used. The level of signiﬁcance was chosen as p < 0.05. All
TABLE 1
Characteristics of the Study Subjects
Gender n (%)
Male 18 (36.7)
Female 31 (63.3)
Age (years) Mean (range)
Male 45 (26–65)
Female 41 (24–60)
All subjects 43 (24–65)
Smoking status Smokers (%) Nonsmokers (%)
Male 2 (11.1) 16 (88.9)
Female 4 (12.9) 27 (87.1)
All subjects 6 (12.2) 43 (87.8)
Ratio of GA-Hb AA-Hb (pmol/g globin) GA-Hb (pmol/g globin)
Mean ± SE Median (range) Mean ± SE Median (range) Mean ± SE Median (range)
Male 0.48 ± 0.05 0.46 (0.12–0.91) 55.30 ± 8.00 47 (18–154) 24.20 ± 3.50 21 (7–67)
Female 0.56 ± 0.04 0.50 (0.24–1.08) 53.20 ± 8.60 40 (19–211) 29.00 ± 4.50 18 (8–99)
Smokers 0.52 ± 0.10 0.45 (0.29–0.98) 154.00 ± 19.00 * 166 (99–211) * 76.50 ± 10.74* 83 (29–99)*
Nonsmokers 0.54 ± 0.03 0.49 (0.12–1.08) 40.00 ± 2.25 37 (18–97) 20.41 ± 1.34 18 (7–46)
All subjects 0.53 ± 0.03 0.49 (0.12–1.08) 53.10 ± 6.20 37 (18–211) 27.30 ± 3.10 19 (7–99)
Note. *Signiﬁcantly higher levels of hemoglobin adducts in smokers compared with nonsmokers (p < 0.001 for both), but no signiﬁcant difference of GA-Hb/
AA-Hb ratio in blood between smokers and nonsmokers (p ¼ 0.602). No signiﬁcant difference of GA-Hb/AA-Hb ratio in blood between male and female (p ¼
0.163).
FIG. 1. The ratio of GA-Hb/AA-Hb versus AA-Hb, for nonsmokers and
for all subjects. For all study subjects, there was no association (R
2 ¼ 0.031);
excluding smokers a very weak association was observed (R
2 ¼ 0.12).
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Inc., Chicago, IL).
RESULTS
Participants
The relevant characteristics of the study subjects are
presented in Table 1. Mean age was 41 years (range 24–60)
and 45 years (range 26–65) for the 31 females and the 18
males, respectively. The distributions of smoking status among
the genders were approximately similar (Table 1).
Biomarkers of Exposure in Blood
The Hb adducts of AA (AA-Hb) and GA (GA-Hb) were
detected in all blood samples analyzed, and the mean concen-
trationsfornonsmokerswere40.00±2.25pmol/gglobinand20.41
± 1.34 pmol/g globin for AA-Hb and GA-Hb, respectively. For
smokers, the mean adduct levels were 154.00 ± 19.00 pmol/g
globin and 76.50 ± 10.74 pmol/g globin for AA-Hb and GA-Hb,
respectively. The smokers had signiﬁcantly higher concentrations
ofHbadductsincomparisonwithnonsmokers(p<0.001forboth).
Therewerenosigniﬁcantdifferencesbetweenmalesandfemalesin
the ratio of GA-Hb versus AA-Hb adduct levels (Table 1). There
wasno(allsubjects)oraverysmall(nonsmokersonly)association
between the ratio of GA-Hb/AA-Hb versus AA-Hb (Fig. 1). The
ratio of GA-HB/AA-Hb data for nonsmokers and for all subjects
were normally distributed (Supplementary Figs. 1A–D).
Genotype Distributions and Association with the Biomarkers
of AA Exposure in Blood
The genotype distributions and allele frequencies of the
study subjects are shown in Table 2. The frequencies of the
TABLE 2
Genotype Distributions and Allele Frequencies of the Subjects
Frequency
Genotype/allele Male, n (%) Female, n (%) p Value Nonsmokers, n ¼ 43 (%) All subjects, n ¼ 49 (%)
CYP2E1 (Val179Ile)
Val/Val 14 (77.8) 30 (96.8) 39 (90.7) 44 (89.8)
Val/Ile 4 (22.2) 1 (3.2) 4 (9.3) 5 (10.2)
Ile/Ile 0 (0.0) 0 (0.0) 0.054 0 (0.0) 0 (0.0)
Val/Ile þ Ile/Ile 4 (22.2) 1 (3.2) 4 (9.3) 5 (10.2)
CYP2E1 (Phe421Phe)
Phe/Phe (C/C) 11 (61.1) 21 (67.7) 30 (69.8) 32 (65.3)
Phe/Phe (T/C) 6 (33.3) 6 (19.4) 10 (23.3) 12 (24.5)
Phe/Phe (T/T) 1 (5.6) 4 (12.9) 0.542 3 (7.0) 5 (10.2)
Phe/Phe (C/TþT/T) 7 (38.9) 10 (32.3) 13 (30.2) 17 (34.7)
EPHX1 (Tyr113His)
Tyr/Tyr 7 (38.9) 21(67.7) 27 (62.8) 28 (57.1)
Tyr/His 8 (44.4) 8 (25.8) 12 (27.9) 16 (32.7)
His/His 3 (16.7) 2 (6.5) 0.812 4 (9.3) 5 (10.2)
Tyr/His þ His/His 11 (61.1) 10 (32.3) 16 (37.2) 21 (42.9)
EPHX1 (His139Arg)
His/His 14 (77.8) 19 (61.3) 27 (62.8) 33 (67.3)
His/Arg 3 (16.7) 9 (29.0) 12 (27.9) 12 (24.5)
Arg/Arg 1 (5.6) 3 (9.7) 0.790 4 (9.3) 4 (8.2)
His/Arg þ Arg/Arg 4 (22.3) 12 (38.7) 16 (37.2) 16 (32.7)
GSTP1 (Ile105Val)
Ile/Ile 7 (38.9) 18 (58.1) 23 (53.5) 25 (51.0)
Ile/Val 8 (44.4) 8 (25.8) 13 (30.2) 16 (32.7)
Val/Val 3 (16.7) 5 (16.1) 0.375 7 (16.3) 8 (16.3)
Ile/Val þ Val/Val 11 (61.1) 13 (41.9) 20 (46.5) 24 (49.0)
GSTM1
Positive 13 (72.2) 27 (87.1) 37 (86.0) 40 (81.6)
Null 5 (27.8) 4 (12.9) 0.259 6 (14.0) 9 (18.4)
GSTT1
Positive 11 (61.1) 13 (41.9) 23 (53.5) 24 (49.0)
Null 7 (38.9) 18 (58.1) 0.244 20 (46.5) 25 (51.0)
Note. There are no signiﬁcant differences in genotype frequencies between genders, and also no signiﬁcant differences in genotype distributions between the
nonsmokers subjects and all subjects.
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0.10 and 0.35, respectively (Table 2). CYP2E1 (Val179Ile)
which is a mis-sense transition mutation, has not been shown to
have any effect on the enzymatic activity (Fairbrother et al.,
1998; Hanioka et al., 2003), whereas CYP2E1 (Phe421Phe) is
a silent intronic mutation. The frequencies of the EPHX1
113His allele, EPHX1 139Arg allele, and GSTP1 105Val allele
were 0.43, 0.33, and 0.49, respectively. The genotype
distributions in this study were in Hardy-Weinberg equilib-
rium, except for CYP2E1 Phe421Phe allele, and the frequen-
cies of the alleles are in agreement with those found in other
Caucasian populations (The International HapMap Project,
2003; Thorisson et al., 2005).
Large variations have been reported in the frequencies of
GSTT1 and GSTM1 deletion among different ethnicities. In
our study the frequency of GSTT1 null genotype was 51%, and
that of GSTM1 null genotype was 18% (Table 2). The range of
values reported for Caucasian populations is 10–20% for
GSTT1 and 40–50% for GSTM1 (Garte et al., 2001; Nelson
et al., 1995; Rebbeck, 1997). Our study subjects hence show
a genotype distribution which is unexpected and different from
these ranges.
Because GA is the genotoxic metabolite of AA, a most
relevant biomarker of exposure to AA is the molar ratio of GA-
Hb and AA-Hb. We therefore tested the association of this
biomarker with the various polymorphisms. For the CYP2E1
genotypes, we found no signiﬁcant association with the ratio of
GA-Hb/AA-Hb levels (Table 3). For the EPHX1 genotype, we
found that individuals with the EPHX1 139Arg allele in exon
4, corresponding to increased enzyme activity, had signiﬁcantly
higher ratio of GA-Hb/AA-Hb compared with individuals with
the wild-type allele 139His (p ¼ 0.007) (Table 3). The 139Arg
allele also gave strongly reduced absolute AA-Hb concentra-
tions, which is contrary to what was expected. For the GST
genotypes, we found a statistically signiﬁcant association with
the GSTM1 and GSTT1 genotypes (p ¼ 0.039 and p ¼ 0.006,
TABLE 3
Genotype Distributions and their Association with the Biomarkers of AA Exposure in Blood
Genotype
No. of
subjects
Mean ratio of
GA-Hb/AA-Hb ± SE p Value
Mean AA-Hb
(pmol/g globin) ± SE p Value
Mean GA-Hb
(pmol/g globin) ± SE p Value
CYP2E1 (Val179Ile)
Val/Val 44 0.52 ± 0.03 52.10 ± 5.70 25.82 ± 3.10
Val/Ile 5 0.70 ± 0.08 0.061 70.56 ± 35.46 0.987 40.04 ± 15.00 0.096
Ile/Ile 0 — — —
CYP2E1 (Phe421Phe)
Phe/Phe (C/C) 32 0.51 ± 0.03 47.00 ± 4.62 22.56 ± 2.12
Phe/Phe (T/C) 12 0.58 ± 0.06 0.224 63.50 ± 18.31 0.969 32.63 ± 8.76 0.490
Phe/Phe (T/T) 5 0.58 ± 0.12 0.846 76.63 ± 30.00 0.780 44.60 ± 17.48 0.589
Phe/Phe (C/T þ T/T) 17 0.58 ± 0.05 0.275 67.35 ± 15.15 0.925 36.15 ± 7.85 0.411
EPHX1 (Tyr113His)
Tyr/Tyr 28 0.54 ± 0.04 42.53 ± 3.01 23.20 ± 3.12
Tyr/His 16 0.53 ± 0.04 0.971 75.80 ± 16.60 0.655 36.80 ± 7.45 0.211
His/His 5 0.53 ± 0.16 0.752 48.10 ± 13.75 0.865 19.70 ± 4.27 0.981
Tyr/His þ His/His 21 0.53 ± 0.05 0.928 69.20 ± 13.17 0.772 32.72 ± 5.93 0.292
EPHX1 (His139Arg)
His/His 33 0.48 ± 0.03 64.00 ± 8.54 30.13 ± 4.48
His/Arg 12 0.65 ± 0.07 0.023* 34.03 ± 2.50 0.007** 22.30 ± 2.94 0.849
Arg/Arg 4 0.62 ± 0.07 0.073 31.31 ± 4.50 0.039** 18.65 ± 2.56 0.463
His/Arg þ Arg/Arg 16 0.64 ± 0.05 0.007* 33.34 ± 2.13 0.002** 21.40 ± 2.30 0.620
GSTP1 (Ile105Val)
Ile/Ile 25.0 0.55 ± 0.04 45.90 ± 6.70 24.45 ± 4.10
Ile/Val 16.0 0.50 ± 0.05 0.781 68.12 ± 13.53 0.132 32.16 ± 6.60 0.112
Val/Val 8.0 0.56 ± 0.06 0.853 50.92 ± 15.00 0.984 26.33 ± 6.25 0.397
Ile/Val þ Val/Val 24 0.52 ± 0.04 0.913 62.40 ± 10.30 0.270 30.22 ± 4.81 0.108
GSTM1
Positive 40 0.50 ± 0.03 47.10 ± 5.46 22.00 ± 2.50
Null 9 0.68 ± 0.08 0.039* 84.44 ± 21.00 0.053 50.74 ± 10.20 0.001***
GSTT1
Positive 24 0.45 ± 0.03 46.00 ± 5.76 19.41 ± 2.46
Null 25 0.61 ± 0.04 0.006* 62.26 ± 11.00 0.335 35.46 ± 5.46 0.001***
Note. *Signiﬁcant associations between GSTT1, GSTM1 and EPHX1 139Arg genotypes and GA-Hb/AA-Hb ratio levels in blood, p < 0.05. **Signiﬁcant
associations between EPHX1 139Arg allele and AA-Hb adduct concentration, p < 0.05. ***Signiﬁcant associations between GSTM1 and GSTT1 genotypes and
GA-Hb adduct concentration, p < 0.05. The numbers in italics indicate the p-value for each calculated association.
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increased (Table 3). In addition the absolute concentrations of
GA-Hb were signiﬁcantly increased for the null genotypes for
both enzymes.
The ratio and the absolute concentrations of GA-Hb and
AA-Hb adducts were also analyzed with respect to their
association with the combined genotypes. We found signiﬁcant
associations between individuals with the double combination
variant of GSTM1-null plus GSTT1-null (p ¼ 0.029), and
CYP2E1 (Val/Val) plus GSTM1 null (p ¼ 0.022); both the
ratio of GA-Hb/AA-Hb and the absolute GA-Hb adduct
concentration for these combined variants were signiﬁcantly
higher in comparison with individuals which did not carry
these genotype combinations (Table 4). The triple combination
CYP2E1 (Val/Val), GSTM1 null and GSTT1 null, was also
signiﬁcantly associated with both increased adduct ratios and
the absolute GA-Hb adduct concentration, p ¼ 0.047 and p ¼
0.033, respectively (Table 4). There was also a signiﬁcant
association between the combination CYP2E1 (Val179Val),
GSTT1 null, EPHX1 (Tyr113Tyr), and EPHX1 (His139Arg),
and the ratio of GA-Hb/AA-Hb adduct level, p ¼ 0.018 (Table 4).
This means that individuals with these combined genotypes
have signiﬁcantly higher blood ratio of GA-Hb/AA-Hb levels,
compared with individuals which did not carry these
genotypes. Because the smokers had signiﬁcantly higher AA-
Hb and GA-Hb adduct concentration than nonsmokers, we
reanalyzed the data for nonsmoking subjects. When the data for
the six smokers were excluded and the associations were
analyzed for the remaining individuals (43 nonsmokers), we
observed similar trends as those for the whole study subjects,
but the associations were slightly weaker with higher p values
(Table 5). This suggests that the adduct level ratios were not
affected by the high AA-Hb concentrations in smokers. The
other polymorphic combinations were not statistically signiﬁcant
(data not shown). Attempts to correlate the AA-Hb level with the
intake of AA-rich food, from food frequency questionnaires,
without taking into account the polymorphisms in biotransfor-
mation enzymes, were unsuccessful. In a new study, using a
revised database for AA content in various food items, a positive
association was indeed found (Brantsaeter et al.,2 0 0 8 ) .
DISCUSSION
In rodents, AA is metabolized by CYP2E1 to the genotoxic
epoxide GA which forms adducts with DNA and proteins
(Ghanayem et al., 2005; Sumner et al., 1999). Conjugation
with glutathione is a major detoxiﬁcation pathway for both AA
and GA. Genetic polymorphisms affecting enzymes involved
in AA biotransformation could be important determinants of
the individual variability of AA metabolism and therefore the
individual susceptibility; this also concerns many other human
xenobiotic metabolizing enzymes (Schoket et al., 2001).
We recently reported major interindividual variations in the
dietary intake of AA estimated from food frequency ques-
tionnaires (Bjellaas et al., 2007). These were however neither
associated with the observed levels of AA-Hb nor the GA-Hb
in blood (data not shown). The AA-Hb adduct concentration
will be a marker for the internal AA dose, whereas the resulting
GA-Hb concentration is a marker of the internal genotoxic
TABLE 4
Association between Combined Genotypes and Biomarkers of AA Exposure in Blood
Joint effects
No. of
subjects
Mean ratio of
GA-Hb/AA-Hb ± SE p Value
Mean AA-Hb
(pmol/g globin) ± SE p Value
Mean GA-Hb
(pmol/g globin) ± SE p Value
GSTM1 and GSTT1
Ref 42 0.50 ± 0.03 49.70 ± 5.80 23.32 ± 2.62
GSTM1-null þ GSTT1-null 7 0.71 ± 0.09 0.029* 79.60 ± 24.50 0.196 51.00 ± 12.80 0.006**
CYP2E1 and GSTM1
Ref 41 0.50 ± 0.03 51.10 ± 6.65 23.90 ± 3.10
CYP2E1 (Val/Val) þ GSTM1-null 8 0.70 ± 0.09 0.022* 68.70 ± 15.57 0.175 44.71 ± 9.30 0.003**
CYP2E1, GSTM1, and GSTT1
Ref 44 0.52 ± 0.03 52.90 ± 6.65 25.10 ± 3.03
CYP2E1 (Val/Val) þ GSTM1-null þ
GSTT1-null
5 0.74 ± 0.12 0.047* 63.40 ± 14.50 0.236 46.54 ± 13.74 0.033**
CYP2E1, GSTT1, and EPHX1
Ref. 45 0.51 ± 0.03 55.64 ± 6.61 27.20 ± 3.40
CYP2E1(Val/Val) þ GSTT1-null þ
EPHX1 (Tyr/Tyr) þ EPHX1 (His/Arg)
4 0.79 ± 0.11 0.018* 35.10 ± 2.90 0.385 28.10 ± 6.00 0.347
Note. *Signiﬁcant associations between individuals with the combination variant of GSTM1 null and GSTT1 null, CYP2E1 (Val179Val) and GSTM1 null,
CYP2E1 (Val/Val), GSTM1 null and GSTT1 null, and CYP2E1 (Val179Val), GSTT1 null, EPHX1 (Tyr113Tyr) and EPHX1 (His139Arg), and GA-Hb/AA-Hb
ratio levels, p < 0.05. **Signiﬁcant association between individuals with the combination variant of GSTM1 null and GSTT1 null, CYP2E1 (Val179Val) and
GSTM1 null, and CYP2E1 (Val/Val), GSTM1 null and GSTT1 null, and GA-Hb adduct concentration, p < 0.05. The presence of the combination of the other
genotypes was taken as the reference (or wild-type) group. The numbers in italics indicate the p-value for each calculated association.
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concentration in assessing the role of biotransformation
enzymes for the internal genotoxic dose, we compensate both
for variations in external AA exposure and also for variations
in the inﬂuence of enzymatic removal of AA. Hence, the ratio
of GA-Hb to AA-Hb is expected to be a biomarker of AA-
related genotoxic exposure. This ratio varied considerably
(ninefold) between the individuals in this study.
Our primary aim was to investigate whether the observed
interindividual variations could be related to polymorphic
differences in the genes CYP2E1, EPHX1, GSTM1, GSTT1,
and GSTP1, either alone or in combination. It would be expected
that the net level of GA-Hb—resulting from endogenously
formed GA—results from a combination of metabolic reactions
as depicted in Figure 2. Maximum GA is expected with the most
efﬁcient CYP2E1 genotype, and—at the same time—the least
efﬁcient genotypes of GSTM1, GSTP1, GSTT1, and the least
efﬁcient genotype of EPHX1. The minimum GA levels would
be expected with the inverse genotype combinations.
We observed that individuals with GSTM1- and GSTT1-null
phenotype have signiﬁcantly higher ratio of GA-Hb/AA-Hb
compared with individuals without these genotypes, and these
individuals may therefore be prone to increased risk resulting
from the decreased enzymatic activity in removal of both AA
and GA. The null genotypes were both associated with
increased absolute AA- and GA-Hb adduct concentrations.
Analysis of the combined effects of various combinations of
genotypes (Table 4) indicates that individuals with some
speciﬁc genotype combinations had signiﬁcantly higher ratio of
GA-Hb/AA-Hb in the blood. These combinations were (1)
GSTM1- and GSTT1- null; (2) CYP2E1 179Val and GSTM1
null; (3) CYP2E1 179Val, GSTM1 null and GSTT1 null; (4)
CYP2E1 179Val, GSTT1 null, EPHX1 113Tyr and EPHX1
139Arg. The observed associations may be explained by the
biological roles of these enzymes in activation/deactivation as
discussed above (Fig. 2). However, the combination (4) was
unexpected because the EPHX1 genotype combinations are
assumed to give increased enzymatic activity (Benhamou et al.,
1998; Hassett et al., 1994) and a concomitant reduced
concentration of GA. The EPHX1 139Arg allele unexpectedly,
contrary to our expectations of high activity (Fig. 2), was
associated with an increased relative concentration of GA-Hb.
In individuals with the EPHX1 139Arg (high activity) alleles,
the AA-Hb adduct concentrations were signiﬁcantly lower
TABLE 5
Association between Genotypes and Biomarkers of AA Exposure in Blood for Nonsmoker Subjects (n 5 43)
Genotype
No. of
subjects
Mean ratio of
GA-Hb/AA-Hb ± SE p Value
Mean AA-Hb
(pmol/g globin) ± SE p Value
Mean GA-Hb
(pmol/g globin) ± SE p Value
EPHX1 (His139Arg)
His/His 27 0.47 ± 0.03 44.00 ± 3.14 19.83 ± 1.67
His/Arg þ Arg/Arg 16 0.64 ± 0.05 0.008* 33.34 ± 2.13 0.014** 21.40 ± 2.30 0.593
GSTM1
Positive 37 0.51 ± 0.03 38.50 ± 2.01 18.50 ± 1.10
Null 6 0.70 ± 0.09 0.042* 49.40 ± 10.20 0.344 32.22 ± 4.70 0.004***
GSTT1
Positive 20 0.46 ± 0.03 39.00 ± 3.00 16.41 ± 1.50
Null 23 0.62 ± 0.04 0.012* 41.20 ± 3.60 0.638 24.44 ± 2.03 0.002***
Joint genotype effects
GSTM1 and GSTT1
Ref 38 0.51 ± 0.03 38.80 ± 2.00 18.90 ± 1.13
GSTM1-null þ GSTT1-null 5 0.71 ± 0.11 0.078 49.50 ± 12.50 0.543 32.20 ± 5.80 0.021***
CYP2E1 and GSTM1
Ref 37 0.51 ± 0.03 38.50 ± 2.00 18.50 ± 1.20
CYP2E1 (Val/Val) þ GSTM1-null 6 0.70 ± 0.09 0.042* 49.40 ± 10.20 0.344 32.22 ± 4.70 0.004***
CYP2E1, GSTM1, and GSTT1
Ref 39 0.52 ± 0.03 38.52 ± 2.00 19.02 ± 1.11
CYP2E1 (Val/Val) þ GSTM1-null þ
GSTT1-null
4 0.66 ± 0.14 0.244 54.50 ± 14.80 0.244 34.00 ± 7.10 0.031***
CYP2E1, GSTT1, and EPHX1
Ref. 39 0.51 ± 0.03 40.51 ± 2.45 19.63 ± 1.31
CYP2E1(Val/Val) þ GSTT1-null þ
EPHX1 (Tyr/Tyr) þ EPHX1 (His/Arg)
4 0.79 ± 0.11 0.021* 35.06 ± 2.90 0.614 28.10 ± 6.00 0.120
Note. *Signiﬁcant association between individuals with the genotype or combination genotype and GA-Hb/AA-Hb adduct ratio levels, p < 0.05. **Signiﬁcant
association between individuals with the genotype or combination genotype and AA-Hb adduct concentration, p < 0.05. ***Signiﬁcant association between
individuals with the genotype or combination genotype and GA-Hb adduct concentration, p < 0.05. The presence of the combination of the other genotypes was
taken as the reference (or wild-type) group. The numbers in italics indicate the p-value for each calculated association.
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activity) allele (Table 3). The reason for this is unknown. The
exceptional low AA-Hb concentration would be important for
a resulting high GA-Hb/AA-Hb ratio. It should be noted that an
EPHX1 polymorphisms with a low activity can be compen-
sated for by increased expression (Hosagrahara et al., 2004;
Omiecinski et al., 2000). Other combinations of the alleles
studied here did not exhibit any indication of signiﬁcant
association (data not shown).
It has previously been shown that the lack of the GSTT1 gene
increases the genotoxic effects of styrene-7,8-oxide in human
whole-blood lymphocyte cultures, suggesting that GSTT1 is
involved in the detoxiﬁcation of styrene oxide in humans
(Ollikainen et al., 1998). A positive association has also been
reported for ethylene oxide and GSTT1 (Fost et al., 1995).
Recently, Paulsson et al. (2005) studied the Hb-adduct levels after
in vitro incubation of blood from various donors with AA or GA,
and reported that the polymorphisms in the GSTT1 or GSTM1
genes did not affect the adduct levels in blood (Paulsson et al.,
2005). This was however a short-term in vitro exposure whereas
our results are from humans, chronically exposed to AA primarily
via the diet. The GSTM1 gene is one of the most studied genes
related to metabolic polymorphisms and cancer risk. The GSTM1
null genotype has been shown to increase the frequency of
chromosome aberrations after in vitro N-nitrosamine exposure,
and in addition, it has been shown to modulate PAH DNA adduct
levels (Ryberg et al., 1997; Salama et al., 1999).
Interactions between several polymorphic variants have
been reported for other xenobiotics. Ryberg et al. (1997)
studied the interaction between GSTM1 null and GSTP1
105Val genotypes, and observed that individuals with this
combination had signiﬁcantly higher PAH DNA adduct levels
in their lung tissue than the other genotype combinations
(Ryberg et al., 1997). Another study has shown that the
GSTM1 null and GSTP1 105Val allele combination was
associated with a four times increased risk of lung cancer in
individuals exposed to environmental tobacco smoke (Wen-
zlaff et al., 2005). The GSTM1 genotype has been shown to
modulate the levels of PAH DNA adducts, in an interaction
with other genotypes, particul a r l yw i t hG S T P 1a n dC Y P 1 A 1
(Butkiewicz et al., 1998; Ichiba et al., 1994; Ryberg et al.,
1997). In our study of AA, we observed a similar interaction
between the CYP-dependent activation and the GST-
dependent deactivation.
The intake of AA via food may vary markedly between
individuals as indicated by food frequency questionnaires
(Brantsaeter et al., 2008). This variation, but also the ge-
notype combination as suggested in our study, would be
expected to contribute to the overall risk of individuals for
AA-associated disease such as neurotoxicity and cancer. In
particular this applies to the GSTM1 null genotype, which in
addition to increasing the relative and absolute internal dose
of GA also tends to increase the internal AA dose (p ¼ 0.053).
A larger study group would needed to conﬁrm these ﬁndings,
because the data in the present work are based on relatively
few individuals. The gene-environment interaction may
therefore be taken into account in the analysis of epidemio-
logical data.
FIG. 2. Metabolism of AA and GA. The association between AA and its metabolite, with drug metabolizing enzymes.
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Supplementary data are available online at http://toxsci.
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